The investment further increases N4’s stake in the business which is fast becoming a pioneer in neurological research producing new work into understanding the complex profile of conditions such as Alzheimer’s, Parkinson’s and depression.

Backed by Foresight Group, Fullbrook Thorpe Investments and N4, NeuroClin has undergone a transformative period which has included the appointment of the experienced global pharma executive, Jeff Thomis, as its chair, a move into new headquarters located at Eurocentral, launching its maiden Parkinson’s research programme and significantly increasing the headcount to approximately 60 employees.

Allan Dowie, Partner at N4, commented: “We are delighted to announce our increased position and partnership in such an exciting business with incredible market opportunities. We’re proud to back a business which is producing life-changing research for the millions suffering from neurological conditions worldwide.”

Jeff Thomis, NeuroClin Ltd’s chair, added: “It has been very encouraging to see the meaningful partnerships formed over the last three years enabling the clinic to continue to build on its global reputation and further diversify the research base. A strong platform has been developed and we look ahead to further expansion.”